Growth hormone receptor antagonists

Journal of Clinical Endocrinology and Metabolism

Volumn 89, Issue 4, 2004, Pages 1503-1511

  Muller, Alex F ^a   Kopchick, John J ^b   Flyvbjerg, Allan ^c   Van Der Lely, Aart Jan ^d  

^a DEPARTMENT OF SURGERY   (Netherlands)

^b OHIO UNIVERSITY   (United States)

^c AARHUS UNIVERSITY   (Denmark)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE DERIVATIVE; PEGVISOMANT; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; HUMAN GROWTH HORMONE;

ACROMEGALY; CARCINOMA; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; KIDNEY DISEASE; PRIORITY JOURNAL; RETINOPATHY; REVIEW; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; EXPERIMENTAL NEOPLASM; RETINA DISEASE;

ANIMALIA;

ACROMEGALY; ANIMALS; ANTINEOPLASTIC AGENTS; GROWTH HORMONE; HUMAN GROWTH HORMONE; HUMANS; KIDNEY DISEASES; MAMMARY NEOPLASMS, ANIMAL; MOLECULAR STRUCTURE; RECEPTORS, SOMATOTROPIN; RETINAL DISEASES;

EID: 1942473187     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-022049     Document Type: Review

References (123)

1. Ohlsson C, Bengtsson BA, Isaksson OG, Andreassen TT, Slootweg MC 1998 Growth hormone and bone. Endocr Rev 19:55-79
2. Theill LE, Karin M 1993 Transcriptional control of GH expression and anterior pituitary development. Endocr Rev 14:670-689
3. Lesniak MA, Roth J, Gorden P, Gavin III JR 1973 Human growth hormone radioreceptor assay using cultured human lymphocytes. Nat New Biol 241:20-22
4. de Vos AM, Ultsch M, Kossiakoff AA 1992 Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 255:306-312
5. Carter-Su C, Rui L, Herrington J 2000 Role of the tyrosine kinase JAK2 in signal transduction by growth hormone. Pediatr Nephrol 14:550-557
6. Baumann G, Shaw MA, Amburn K 1989 Regulation of plasma growth hormone-binding proteins in health and disease. Metabolism 38:683-689
7. Abdel-Meguid SS, Shieh HS, Smith WW, Dayringer HE, Violand BN, Bentle LA 1987 Three-dimensional structure of a genetically engineered variant of porcine growth hormone. Proc Natl Acad Sci USA 84:6434-6437
8. Waters MJ 1999 The GH receptor. In: Kostoyo JL, Goodman HM, eds. Handbook of physiology. Oxford: Oxford University Press; 397-444
9. Chen WY, Wight DC, Wagner TE, Kopchick JJ 1990 Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice. Proc Natl Acad Sci USA 87:5061-5065
10. Hara K, Sonenberg M 1977 Polyalanylation of bovine somatotropin peptide 96-133. Biochim Biophys Acta 492:95-101
11. Chen WY, White ME, Wagner TE, Kopchick JJ 1991 Functional antagonism between endogenous mouse growth hormone (GH) and a GH analog results in dwarf transgenic mice. Endocrinology 129:1402-1408
12. Chen WY, Wight DC, Mehta BV, Wagner TE, Kopchick JJ 1991 Glycine 119 of bovine growth hormone is critical for growth-promoting activity. Mol Endocrinol 5:1845-1852
13. Fuh G, Cunningham BC, Fukunaga R, Nagata S, Goeddel DV, Wells JA 1992 Rational design of potent antagonists to the human growth hormone receptor. Science 256:1677-1680
14. Chen WY, Chen N, Yun J, Wagner TE, Kopchick JJ 1994 In vitro and in vivo studies of the antagonistic effects of human growth hormone analogs. J Biol Chem 269:20806
15. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ 2002 Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 23:623-646
16. Okada S, Chen WY, Wiehl P, Kelder B, Goodman HM, Guller S, Sonenberg M, Kopchick JJ 1992 A growth hormone (GH) analog can antagonize the ability of native GH to promote differentiation of 3T3-F442A preadipocytes and stimulate insulin-like and lipolytic activities in primary rat adipocytes. Endocrinology 130:2284-2290
17. Pradhananga S, Wilkinson I, Ross RJ 2002 Pegvisomant: structure and function. J Mol Endocrinol 29:11-14
18. Veldhuis JD, Bidlingmaier M, Anderson SM, Evans WS, Wu Z, Strasburger CJ 2002 Impact of experimental blockade of peripheral growth hormone (GH) receptors on the kinetics of endogenous and exogenous GH removal in healthy women and men. J Clin Endocrinol Metab 87:5737-5745
19. Rodvold KA, van der Lely AJ Pharmacokinetics and pharmacodynamics of B2036-PEG, a novel growth hormone receptor antagonist, in acromegalic subjects. Program of the 81st Annual Meeting of The Endocrine Society, San Diego, CA, 1994, p 145 (Abstract P1-49)
20. Cunningham BC, Wells JA 1989 High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. Science 244:1081-1085
21. Thorner MO, Strasburger CJ, Wu Z, Straume M, Bidlingmaier M, Pezzoli SS, Zib K, Scarlett JC, Bennett WF 1999 Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. J Clin Endocrinol Metab 84:2098-2103
22. Goffin V, Touraine P 2002 Pegvisomant. Pharmacia. Curr Opin Invest Drugs 3:752-757
23. Govers R, Van Kerkhof P, Schwartz AL, Strous GJ 1997 Linkage of the ubiquitin-conjugating system and the endocytic pathway in ligand-induced internalization of the growth hormone receptor. EMBO J 16:4851-4858
24. Govers R, Van Kerkhof P, Schwartz AL, Strous GJ 1998 Di-leucine-mediated internalization of ligand by a truncated growth hormone receptor is independent of the ubiquitin conjugation system. J Biol Chem 273:16426-16433
25. Govers R, ten Broeke T, Van Kerkhof P, Schwartz AL, Strous GJ 1999 Identification of a novel ubiquitin conjugation motif, required for ligand-induced internalization of the growth hormone receptor. EMBO J 18:28-36
26. Harding PA, Wang X, Okada S, Chen WY, Wan W, Kopchick JJ 1996 Growth hormone (GH) and a GH antagonist promote GH receptor dimerization and internalization. J Biol Chem 271:6708-6712
27. Maamra M, Finidori J, Von Laue S, Simon S, Justice S, Webster J, Dower S, Ross R 1999 Studies with a growth hormone antagonist and dual-fluorescent confocal microscopy demonstrate that the full-length human growth hormone receptor, but not the truncated isoform, is very rapidly internalized independent of Jak2-Stat5 signaling. J Biol Chem 274:14791-14798
28. Ross RJ, Leung KC, Maamra M, Bennett W, Doyle N, Waters MJ, Ho KK 2001 Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer. J Clin Endocrinol Metab 86:1716-1723
29. Zhang Y, Jiang J, Kopchick JJ, Frank SJ 1999 Disulfide linkage of growth hormone (GH) receptors (GHR) reflects GH-induced GHR dimerization. Association of JAK2 with the GHR is enhanced by receptor dimerization. J Biol Chem 274:33072-33084
30. Melmed S 1990 Acromegaly. N Engl J Med 322:966-977.
31. Melmed S 2001 Acromegaly and cancer: not a problem? J Clin Endocrinol Metab 86:2929-2934
32. Orme SM, McNally RJ, Cartwright RA, Belchetz PE 1998 Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 83:2730-2734
33. Fahlbusch R, Honegger J, Buchfelder M 1992 Surgical management of acromegaly. Endocrinol Metab Clin North Am 21:669-692
34. Swearingen B, Barker FG, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT 1998 Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83:3419-3426
35. Barkan AL, Halasz I, Dornfeld KJ, Jaffe CA, Friberg RD, Chandler WF, Sandler HM 1997 Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab 82:3187-3191
36. Barkan AL 2003 Radiotherapy in acromegaly: the argument against. Clin Endocrinol (Oxf) 58:132-135
37. Barrande G, Pittino-Lungo M, Coste J, Ponvert D, Bertagna X, Luton JP, Bertherat J 2000 Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. J Clin Endocrinol Metab 85:3779-3785
38. Biermasz NR, van Dulken H, Roelfsema F 2000 Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. J Clin Endocrinol Metab 85:2476-2482
39. Powell JS, Wardlaw SL, Post KD, Freda PU 2000 Outcome of radiotherapy for acromegaly using normalization of insulin-like growth factor I to define cure. J Clin Endocrinol Metab 85:2068-2071
40. Thorner MO 2003 Controversy: radiotherapy for acromegaly. Clin Endocrinol (Oxf) 58:136-137
41. van der Lely AJ, de Herder WW, Lamberts SW 1997 The role of radiotherapy in acromegaly. J Clin Endocrinol Metab 82:3185-3186
42. Wass JA 2003 Radiotherapy in acromegaly: a protagonists viewpoint. Clin Endocrinol (Oxf) 58:128-131
43. Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, Mahler C, Beckers A 1998 Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 83:374-378
44. Jaffe CA, Barkan AL 1992 Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am 21:713-735
45. Chanson P, Boerlin V, Ajzenberg C, Bachelot Y, Benito P, Bringer J, Caron P, Charbonnel B, Cortet C, Delemer B, Escobar-Jimenez F, Foubert L, Gaztambide S, Jockenhoevel F, Kuhn JM, Ledere J, Lorcy Y, Perlemuter L, Prestele H, Roger P, Rohmer V, Santen R, Sassolas G, Scherbaum WA, Schopohl J, Torres E, Varela C, Villamil F, Webb SM 2000 Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin Endocrinol (Oxf) 53:577-586
46. Chanson P, Leselbaum A, Blumberg J, Schaison G 2000 Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly. Pituitary 2:269-276
47. Davies PH, Stewart SE, Lancranjan L, Sheppard MC, Stewart PM 1998 Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin Endocrinol (Oxf) 48:311-316
48. Vance ML, Harris AG 1991 Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group. Arch Intern Med 151:1573-1578
49. Herman-Bonert VS, Zib K, Scarlett JA, Melmed S 2000 Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. J Clin Endocrinol Metab 85:2958-2961
50. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO 2001 Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358:1754-1759
51. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ 2000 Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342:1171-1177
52. Utiger RD 2000 Treatment of acromegaly. N Engl J Med 342:1210-1211
53. Ho KY 2001 Place of pegvisomant in acromegaly. Lancet 358:1743-1744
54. van der Lely AJ, Muller A, Janssen JA, Davis RJ, Zib KA, Scarlett JA, Lamberts SW 2001 Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. J Clin Endocrinol Metab 86:478-481
55. Melmed S 2003 Treatment of acromegaly. In: Rose BD, ed. UpToDate. Wellesley, MA: UpToDate
56. Young FG 1937 Permanent diabetes produced by pituitary (anterior lobe) injections. Lancet 2:374.
57. Campbell J, Davidson IWF, Lei HP 1950 The production of permanent diabetes by highly purified growth hormone. Endocrinology 46:590
58. Hansen AP, Johansen K 1970 Diurnal patterns of blood glucose, serum free fatty acids, insulin, glucagon and growth hormone in normals and juvenile diabetics. Diabetologia 6:27-33
59. Yde H 1969 Abnormal growth hormone response to ingestion of glucose in juvenile diabetics. Acta Med Scand 186:499-504
60. Lundbaek K, Christensen NJ, Jensen VA, Johansen K, Olsen TS, Hansen AP, Orskov H, Osterby R 1970 Diabetes, diabetic angiopathy, and growth hormone. Lancet 2:131-133
61. Yde H 1969 The growth hormone dependent sulfation factor in serum from patients with various types of diabetes. Acta Med Scand 186:293-297
62. Flyvbjerg A 1990 Growth factors and diabetic complications. Diabet Med 7:387-399
63. Flyvbjerg A 2000 Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Diabetologia 43:1205-1223
64. Janssen JA, Lamberts SW 2000 Circulating IGF-I and its protective role in the pathogenesis of diabetic angiopathy. Clin Endocrinol (Oxf) 52:1-9
65. Flyvbjerg A, Bennett WF, Rasch R, Kopchick JJ, Scarlett JA 1999 Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy, and urinary albumin excretion in experimental diabetes in mice. Diabetes 48:377-382
66. Flyvbjerg A, Orskov H, Alberti G 1993 Growth hormone and insulin-like growth factor I in human and experimental diabetes. Chichester, New York, Brisbane, Toronto, Singapore: Wiley; 1-123
67. Flyvbjerg A, Landau D, Domene H, Hernandez L, Gronbaek H, LeRoith D 1995 The role of growth hormone, insulin-like growth factors (IGFs), and IGF-binding proteins in experimental diabetic kidney disease. Metabolism 44:67-71
68. Flyvbjerg A, Frystyk J, Thorlacius-Ussing O, Orskov H 1989 Somatostatin analogue administration prevents increase in kidney somatomedin C and initial renal growth in diabetic and uninephrectomized rats. Diabetologia 32:261-265
69. Flyvbjerg A, Marshall SM, Frystyk J, Hansen KW, Harris AG, Orskov H 1992 Octreotide administration in diabetic rats: effects on renal hypertrophy and urinary albumin excretion. Kidney Int 41:805-812
70. Landau D, Segev Y, Afargan M, Silbergeld A, Katchko L, Podshyvalov A, Phillip M 2001 A novel somatostatin analogue prevents early renal complications in the nonobese diabetic mouse. Kidney Int 60:505-512
71. Gronbaek H, Vogel I, Osterby R, Lancranjan I, Flyvbjerg A, Orskov H 1998 Effect of octreotide, captopril or insulin on renal changes and UAE in long-term experimental diabetes. Kidney Int 53:173-180
72. Chen NY, Chen WY, Bellush L, Yang CW, Striker LJ, Striker GE, Kopchick JJ 1995 Effects of streptozotocin treatment in growth hormone (GH) and GH antagonist transgenic mice. Endocrinology 136:660-667
73. Chen NY, Chen WY, Kopchick JJ 1996 A growth hormone antagonist protects mice against streptozotocin induced glomerulosclerosis even in the presence of elevated levels of glucose and glycated hemoglobin. Endocrinology 137: 5163-5165
74. Bellush LL, Doublier S, Holland AN, Striker LJ, Striker GE, Kopchick JJ 2000 Protection against diabetes-induced nephropathy in growth hormone receptor/binding protein gene-disrupted mice. Endocrinology 141:163-168
75. Segev Y, Landau D, Rasch R, Flyvbjerg A, Phillip M 1999 Growth hormone receptor antagonism prevents early renal changes in nonobese diabetic mice. J Am Soc Nephrol 10:2374-2381
76. Flyvbjerg A, Rasch R, Effect of growth hormone (GH) receptor antagonist (G120K-PEG) treatment on manifest renal changes in non-obese diabetic (NOD) mice. Proc 32nd Meeting of the American Society of Nephrology, Miami Beach, FL, 1999 (Abstract 3443)
77. Serri O, Beauregard H, Brazeau P, Abribat J, Lambert J, Harris A, Vachon L 1991 Somatostatin analogue, octreotide, reduces increased glomerular filtration rate and kidney size in insulin-dependent diabetes. JAMA 265:888-892
78. Jacobs ML, Derkx FH, Stijnen T, Lamberts SW, Weber RF 1997 Effect of long-acting somatostatin analog (Somatulin) on renal hyperfiltration in patients with IDDM. Diabetes Care 20:632-636
79. Poulsen JE 1953 The Houssay phenomenon in man: recovery from retinopathy in a case of diabetes with Simmond's disease. Diabetes 2:7-12
80. Poulsen JE 1966 Diabetes and anterior pituitary insufficiency. Final course and postmortem study of a diabetic patient with Sheehan's syndrome. Diabetes 15:73-77
81. Boehm BO, Lang GK, Jehle PM, Feldman B, Lang GE 2001 Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm Metab Res 33:300-306
82. Grant MB, Mames RN, Fitzgerald C, Hazariwala KM, Cooper-DeHoff R, Caballero S, Estes KS 2000 The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care 23:504-509
83. Mallet B, Vialettes B, Haroche S, Escoffier P, Gastaut P, Taubert JP, Vague P 1992 Stabilization of severe proliferative diabetic retinopathy by long-term treatment with SMS 201-995. Diabete Metab 18:438-444
84. Van Hagen PM, Baarsma GS, Mooy CM, Ercoskan EM, ter Averst E, Hofland LJ, Lamberts SW, Kuijpers RW 2000 Somatostatin and somatostatin receptors in retinal diseases. Eur J Endocrinol 143(Suppl 1):S43-S51
85. Smith LE, Kopchick JJ, Chen W, Knapp J, Kinose F, Daley D, Foley E, Smith RG, Schaeffer JM 1997 Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 276:1706-1709
86. Growth Hormone Antagonist for Proliferative Diabetic Retinopathy Study Group 2001 The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy. Ophthalmology 108:2266-2272
87. Simo R, Lecube A, Sararols L, Garcia-Arumi J, Segura RM, Casamitjana R, Hernandez C 2002 Deficit of somatostatin-like immunoreactivity in the vitreous fluid of diabetic patients: possible role in the development of proliferative diabetic retinopathy. Diabetes Care 25:2282-2286
88. Parkinson C, Drake WM, Roberts ME, Meeran K, Besser GM, Trainer PJ 2002 A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal. J Clin Endocrinol Metab 87:1797-1804
89. Pollak M, Blouin MJ, Zhang JC, Kopchick JJ 2001 Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist. Br J Cancer 85:428-430
90. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M 1998 Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279:563-566
91. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M 1998 Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351:1393-1396
92. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ 1999 Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91:620-625
93. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE 2000 The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21:215-244
94. O'Dell SD, Day IN 1998 Insulin-like growth factor II (IGF-II). Int J Biochem Cell Biol 30:767-771
95. Osborne CK, Clemmons DR, Arteaga CL 1990 Regulation of breast cancer growth by insulin-like growth factors. J Steroid Biochem Mol Biol 37:805-809
96. Friend KE, Radinsky R, McCutcheon IE 1999 Growth hormone receptor expression and function in meningiomas: effect of a specific receptor antagonist. J Neurosurg 91:93-99
97. McCutcheon IE, Flyvbjerg A, Hill H, Li J, Bennett WF, Scarlett JA, Friend KE 2001 Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J Neurosurg 94:487-492
98. Huisman TW, Tanghe HL, Koper JW, Reubi JC, Foekens JA, Avezaat CJ, Braakman R, Lamberts SW 1991 Progesterone, oestradiol, somatostatin and epidermal growth factor receptors on human meningiomas and their CT characteristics. Eur J Cancer 27:1453-1457
99. Koper JW, Markstein R, Kohler C, Kwekkeboom DJ, Avezaat CJ, Lamberts SW, Reubi JC 1992 Somatostatin inhibits the activity of adenylate cyclase in cultured human meningioma cells and stimulates their growth. J Clin Endocrinol Metab 74:543-547
100. Jenkins PJ, Fairclough PD, Richards T, Lowe DG, Monson J, Grossman A, Wass JA, Besser M 1997 Acromegaly, colonic polyps and carcinoma. Clin Endocrinol (Oxf) 47:17-22
101. Alonso M, Galera MJ, Reyes G, Calabuig R, Vinals A, Rius X 1992 Effects of pentagastrin and of the somatostatin analog (SMS 201-995) on growth of CT26 in vivo adenocarcinoma of the colon. Surg Gynecol Obstet 175:441-444
102. Dy DY, Whitehead RH, Morris DL 1992 SMS 201.995 inhibits in vitro and in vivo growth of human colon cancer. Cancer Res 52:917-923
103. Qin Y, Serially AV, Willems G 1991 Somatostatin analogue RC-160 inhibits the growth of transplanted colon cancer in rats. Int J Cancer 47:765-770
104. Smith JP, Solomon TE 1988 Effects of gastrin, proglumide, and somatostatin on growth of human colon cancer. Gastroenterology 95:1541-1548
105. Qin Y, Schally AV, Willems G 1992 Treatment of liver metastases of human colon cancers in nude mice with somatostatin analogue RC-160. Int J Cancer 52:791-796
106. Duan H, Dagnaes-Hansen F, Rasmussen L, Friend KE, Orskov H, Bennett WF, Flyvbjerg A, GH receptor antagonist treatment inhibits growth of human colorectal carcinoma, COLO205 in nude mice. Free 5th International Symposium on Insulin-Like Growth Factors Brighton, United Kingdom, 1999 (Abstract P 13)
107. Friend KE 2000 Targeting the growth hormone axis as a therapeutic strategy in oncology. Growth Horm IGF Res 10(Suppl A):S45-S46
108. Iftikhar SY, Watson SA, Morris DL 1991 The effect of long acting somatostatin analogue SMS 201.995 therapy on tumour kinetic measurements and serum tumour marker concentrations in primary rectal cancer. Br J Cancer 63:971-974
109. Cascinu S, Del Ferro E, Catalano G 1995 A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy. Br J Cancer 71:97-101
110. Cascinu S, Del Ferro E, Grianti C, Ligi M, Ghiselli R, Foglietti G, Saba V, Lungarotti F, Catalano G 1997 Inhibition of tumor cell kinetics and serum insulin growth factor I levels by octreotide in colorectal cancer patients. Gastroenterology 113:767-772
111. Goldberg RM, Moertel CG, Wieand HS, Krook JE, Schutt AJ, Veeder MH, Mailliard JA, Dalton RJ 1995 A phase III evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma. North Central Cancer Treatment Group and the Mayo Clinic. Cancer 76:961-966
112. Peyrat JP, Bonneterre J, Hecquet B, Vennin P, Louchez MM, Fournier C, Lefebvre J, Demaille A 1993 Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer 29A:492-497.
113. Vennin P, Peyrat JP, Bonneterre J, Louchez MM, Harris AG, Demaille A 1989 Effect of the long-acting somatostatin analogue SMS 201-995 (Sandostatin) in advanced breast cancer. Anticancer Res 9:153-155
114. Di Leo A, Ferrari L, Bajetta E, Bartoli C, Vicario G, Moglia D, Miceli R, Callegari M, Bono A 1995 Biological and clinical evaluation of lanreotide (B1M 23014), a somatostatin analogue, in the treatment of advanced breast cancer. A pilot study by the I. T. M. O. Group. Italian Trials in Medical Oncology. Breast Cancer Res Treat 34:237-244
115. Canobbio L, Cannata D, Miglietta L, Boccardo F 1995 Somatuline (BIM 23014) and tamoxifen treatment of postmenopausal breast cancer patients: clinical activity and effect on insulin-like growth factor-I (IGF-1) levels. Anticancer Res 15:2687-2690
116. O'Byrne KJ, Dobbs N, Propper DJ, Braybrooke JP, Koukourakis MI, Mitchell K, Woodhull J, Talbot DC, Schally AV, Harris AL 1999 Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer. Br J Cancer 79:1413-1418
117. Ingle JN, Suman VJ, Kardinal CG, Krook JE, Mailliard JA, Veeder MH, Loprinzi CL, Dalton RJ, Hartmann LC, Conover CA, Pollak MN 1999 A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Cancer 85:1284-1292
118. Friend KE, Flyvbjerg A, Bennett WF, McCutcheon IE, The growth hormone receptor antagonist pegvisomant exhibits antitumor activity in multiple preclinical tumor models. Proc 11th NCI-EORTC-AACR Symposium, Amsterdam, The Netherlands, 2000
119. Tode B, Serio M, Rotella CM, Galli G, Franceschelli F, Tanini A, Toccafondi R 1989 Insulin-like growth factor-I: autocrine secretion by human thyroid follicular cells in primary culture. J Clin Endocrinol Metab 69:639-647
120. Hana V, Murphy LJ 1994 Expression of insulin-like growth factors and their binding proteins in the estrogen responsive Ishikawa human endometrial cancer cell line. Endocrinology 135:2511-2516
121. Dunn SE, Kari FW, French J, Leininger JR, Travlos G, Wilson R, Barrett JC 1997 Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-defident mice. Cancer Res 57:4667-4672
122. Dunn SE 2000 Insulin-like growth factor I stimulates angiogenesis and the production of vascular endothelial growth factor. Growth Horm IGF Res 10(Suppl A):S41-S42
123. Hejna M, Schmidinger M, Raderer M 2002 The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? Ann Oncol 13:653-668